The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review)

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 803-809

  Jimi, Eijiro ^a   Shin, Masashi ^b   Furuta, Hiroyuki ^a   Tada, Yukiyo ^a   Kusukawa, Jingo ^c  

^a KYUSHU DENTAL COLLEGE   (Japan)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone invasion; Oral squamous cell carcinomas; Osteoprotegerin; Receptor activator of NF B ligand

Indexed keywords

COLONY STIMULATING FACTOR 1; DENOSUMAB; INTERLEUKIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BONE DENSITY; BONE DESTRUCTION; BONE MARROW CELL; BONE METABOLISM; BONE METASTASIS; CARCINOMA CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; DRUG TARGETING; FRACTURE; HEMATOPOIETIC CELL; HUMAN; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; HUMANS; MANDIBLE; MICE; MOLECULAR TARGETED THERAPY; MOUTH NEOPLASMS; NF-KAPPA B; OSTEOCLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 84873623141     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1794     Document Type: Review

References (54)

1. Haddad RI and Shin DM: Recent advances in head and neck cancer. N Engl J Med 359: 1143-1154, 2008.
2. Cohen EE, Haraf DJ, Kunnavakkam R, et al: Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 28: 3336-3343, 2010.
3. Jimi E, Furuta H, Matsuo K, Tominaga K, Takahashi T and Nakanishi O: The cellular and molecular mechanisms of bone invasion by oral squamous cell carcinoma. Oral Dis 17: 462-468, 2011.
4. Ash CS, Nason RW, Abdoh AA and Cohen MA: Prognostic implications of mandibular invasion in oral cancer. Head Neck 22: 794-798, 2000.
5. Semba I, Matsuuchi H and Miura Y: Histomorphometric analysis of osteoclastic resorption in bone directly invaded by gingival squamous cell carcinoma. J Oral Pathol Med 25: 429-435, 1996. (Pubitemid 26420509)
6. Totsuka Y, Usui Y, Tei K, Fukuda H, Shindo M, Iizuka T, and Amemiya A: Mandibular involvement by squamous cell carcinoma of the lower alveolus: analysis and comparative study of histologic and radiologic features. Head Neck 13: 40-50, 1991.
7. Shibahara T, Noma H, Takasaki Y and Nomura T: Repair of the inferior alveolar nerve with a forearm cutaneous nerve graft after ablative surgery of the mandible. J Oral Maxillofac Surg 58: 714-717, 2000. (Pubitemid 30430519)
8. Shah J and Lydiatt WM: Buccal mucosa, alveolus, retromolar trigone, floor of mouth, hard palate, and tongue tumors. In: Comprehensive Management of Head and Neck Tumors. Thawley SE (ed). 2nd edition. WB Saunders, Philadelphia, PA, pp686-693, 1999.
9. Carter RL, Tsao SW, Burman JF, Pittam MR, Clifford P and Shaw HJ: Patterns and mechanisms of bone invasion by squamous carcinomas of the head and neck. Am J Surg 146: 451-455, 1983. (Pubitemid 13012466)
10. Müller H and Slootweg PJ: Mandibular invasion by oral squamous cell carcinoma. Clinical aspects. J Craniomaxillofac Surg 18: 80-84, 1990. (Pubitemid 20128432)
11. Totsuka Y, Usui Y, Tei K, Kida M, Mizukoshi T, Notani K and Fukuda H: Results of surgical treatment for squamous carcinoma of the lower alveolus: segmental vs. marginal resection. Head Neck 13: 114-120, 1991.
12. Wong RJ, Keel SB, Glynn RJ and Varvares MA: Histological pattern of mandibular invasion by oral squamous cell carcinoma. Laryngoscope 110: 65-72, 2000. (Pubitemid 30046648)
13. Guise TA and Mundy GR: Cancer and bone. Endocr Rev 19: 18-54, 1998. (Pubitemid 29122073)
14. Shibahara T, Nomura T, Cui NH and Noma H: A study of osteoclast-related cytokines in mandibular invasion by squamous cell carcinoma. Int J Oral Maxillofac Surg 34: 789-793, 2005.
15. Yasuda H, Shima N, Nakagawa N, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-3602, 1998.
16. Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998. (Pubitemid 28180851)
17. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T and Higashio K: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234: 137-142, 1997. (Pubitemid 27267548)
18. Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997. (Pubitemid 27199902)
19. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT and Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999. (Pubitemid 30649812)
20. Lee Y, Schwarz E, Davies M, et al: Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 21: 62-72, 2003. (Pubitemid 36157621)
21. Miller RE, Branstetter D, Armstrong A, et al: Receptor activator of NF-κB ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol 179: 266-274, 2007. (Pubitemid 46986542)
22. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET and Dougall WC: RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68: 92-104, 2008.
23. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ and Dougall WC: Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25: 119-129, 2008.
24. Wada T, Nakashima T, Hiroshi N and Penninger JM: RANKL RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12: 17-25, 2006. (Pubitemid 43089652)
25. Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature 423: 337-342, 2003. (Pubitemid 40852708)
26. Mizuno A, Amizuka N, Irie K, et al: Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247: 610-615, 1998. (Pubitemid 28418439)
27. Wong BR, Rho J, Arron J, et al: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272: 25190-25194, 1997. (Pubitemid 27415705)
28. Kong YY, Yoshida H, Sarosi I, et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323, 1999.
29. Anderson DM, Maraskovsky E, Billingsley WL, et al: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179, 1997. (Pubitemid 27507987)
30. Jimi E, Akiyama S, Tsurukai T, et al: Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163: 434-442, 1999. (Pubitemid 29295871)
31. Dougall WC, Glaccum M, Charrier K, et al: RANK is essential for osteoclast and lymph node development. Genes Dev 13: 2412-2424, 1999. (Pubitemid 29453612)
32. Body JJ, Facon T, Coleman RE, et al: A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 1221-1228, 2006. (Pubitemid 43342512)
33. Bendre M, Gaddy D, Nicholas RW and Suva LJ: Breast cancer metastasis to bone: it is not all about PTHrP. Clin Orthop Relat Res 415: S39-S45, 2003. (Pubitemid 37323318)
34. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ and Gillespie MT: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458, 1999. (Pubitemid 30666108)
35. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M and Vessella RL: Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 57: 611-616, 2001.
36. Sezer O, Heider U, Zavrski I, Kühne CA and Hofbauer LC: RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101: 2094-2098, 2003. (Pubitemid 36302042)
37. Yaccoby S, Wezeman MJ, Henderson A, Kühne CA and Hofbauer LC: Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 64: 2016-2023, 2004. (Pubitemid 38339448)
38. Nagai M, Kyakumoto S and Sato N: Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 269: 532-536, 2000. (Pubitemid 30440335)
39. Tada T, Jimi E, Okamoto M, Ozeki S and Okabe K: Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. Int J Cancer 116: 253-262, 2005. (Pubitemid 40967262)
40. Kayamori K, Sakamoto K, Nakashima T, et al: Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am J Pathol 176: 968-980, 2010.
41. Chuang FH, Hsue SS, Wu CW and Chen YK: Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma. J Oral Pathol Med 38: 753-759, 2009.
42. Farrugia AN, Atkins GJ, To LB, et al: Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63: 5438-5445, 2003. (Pubitemid 37139862)
43. Giuliani N, Bataille R, Mancini C, Lazzaretti M and Barillé S: Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 3527-3533, 2001.
44. Ohshiba T, Miyaura C, Inada M and Ito A: Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. Biochem Biophys Res Commun 300: 957-964, 2003. (Pubitemid 36259856)
45. Tada T, Shin M, Fukushima H, Okabe K, Ozeki S, Okamoto M and Jimi E: Oral squamous cell carcinoma cells modulate osteoclast function by RANKL-dependent and -independent mechanisms. Cancer Lett 274: 126-131, 2009.
46. Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA and Suda T: Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 247: 84-93, 1999. (Pubitemid 29393964)
47. Jones DH, Nakashima T, Sanchez OH, et al: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696, 2006.
48. Shin M, Matsuo K, Tada T, et al: The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. Carcinogenesis 32: 1634-1640, 2011.
49. Body JJ, Greipp P, Coleman RE, et al: A phase I study of AMGN 0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97: 887-892, 2003. (Pubitemid 36125828)
50. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT and Dunstan CR: The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16: 348-360 2001. (Pubitemid 32105416)
51. Roodman GD and Dougall WC: RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treatment Rev 34: 143-150, 2008.
52. Steger GG and Bartsch R: Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol 3: 233-243, 2011.
53. Kyrgidis A and Toulis KA: Denosumab-related osteonecrosis of the jaws. Osteoporos Int 22: 369-370, 2011.
54. Choi S and Myers JN: Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 87: 14-32, 2008.